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In developed countries, endometrial cancer is the most common
female pelvic malignancy. Although most of these cancers (75%)
are detected at an early stage and present a favourable clinical
outcome, a significant number of patients (10—15%) with localized
disease develop recurrence and distant metastases and die of
cancer (Malkasian et al, 1980; Lotocki et al, 1983). Several clini-
copathological features are currently used as prognostic indicators,
including histological type, histological grade, depth of myome-
trial invasion, surgical stage of disease, vascular invasion, peri-
toneal cytology, cervical extension, lymph node involvement, and
the presence of metastatic disease (Christopherson et al, 1983;
Creasman et al, 1987; Morrow et al, 1991; Barakat et al, 1997).
The identification of new prognostic factors, more closely related
to tumour biology, would be of great interest for their potential
ability to discriminate between patients with low and high risk of
recurrence, and even for treatment planning. In this respect,
oestrogen (ER) and progesterone (PR) receptors (Creasman,
1993), DNA content (ploidy) (Newbury et al, 1990), percentage of
cells in the S-phase of the cell cycle (S-phase) (Rosenberg et al,
1989), and HER-2/neu oncogene (Hetzel et al, 1992) have been
extensively studied in the past years.
Tumour invasion and metastasis are complex processes in
which proteases that promote the breakdown of basement
membrane and extracellular matrix play a central role, cathepsin D
(Cat D) being one of the most studied. Cat D is an acidic aspartil
lysosomal endopeptidase produced as a 52-kDa precursor, which
is then processed to a 48-kDa intermediate, and then to a 34-kDa
mature stable form (Caponi et al, 1986). In human breast cancer
cells, altered normal sorting and maturation resulted in a marked
increase in Cat D secretion (Caponi et al, 1989). Besides its enzy-
matic activity, Cat D is a mitogen, acting through its binding to the
insulin-like growth factor type II receptor (Mathieu et al, 1990).
Cat D expression is controlled by oestrogen and growth factors in
human breast cancer cells (Westley et al, 1980; Rochefort et al,
1990). However, in both human endometrial cancer cell lines
(Touitou et al, 1989), rat uterus (Elangovan et al, 1980), and
normal human endometrium (Maudelonde et al, 1990), Cat D
expression is under regulation by progesterone and growth factors,
but not by oestrogen.
The usefulness of Cat D as a prognostic factor has been exten-
sively studied in breast cancer in which high levels of the protease
have been associated with a worse prognosis either in whole
tumour series or in node-negative or node-positive patients
(Spyratos et al, 1989; Thorpe et al, 1989; Tandon et al, 1990;
Foekens et al, 1993; Ferrandina et al, 1997), although discrepant
findings have also been reported (Ravdin et al, 1994, 1997). In
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contrast, there are few data on Cat D in endometrial cancer, and
only one report deals with its prognostic value (L￿sch et al, 1996).
In the present study, we examined the relationship between Cat
D and established clinicopathological prognostic parameters and
biological predictors in a series of 156 patients with primary
endometrial cancer. The prognostic value of Cat D was also
studied in a subset of 97 patients followed for at least 2 years or
until death. Our results suggest that a low tumoral Cat D content is
predictive of persistent or recurrent disease.
MATERIALS AND METHODS
Patients
This study was performed on 156 consecutive patients diagnosed
with surgical stage I—III primary endometrial cancer between June
1990 and June 1997, and treated at the Department of Obstetrics and
Gynaecology at the Hospital Materno Infantil in Las Palmas (Canary
Islands, Spain). None of the patients had received substitutive
hormonal therapy for at least 3 months before diagnosis. All patients
underwent exploratory laparotomy, total hysterectomy and bilateral
salpingo-oophorectomy. Radiation therapy after surgery was admin-
istered to all patients in stages II and III, and to patients in stage I with
risk factors such as serous and clear cell histological types, deep
myometrial invasion, and high histological grade. The treatment
consisted of irradiation of either the vaginal cuff (45—60 Gy) (n = 8),
the whole pelvis (50 Gy) (n = 5), or both (n = 62). Additionally, two
patients received irradiation in the whole pelvis and in the para-aortic
nodes (45 Gy). Complete clinical information was obtained for all
patients. This included age at diagnosis, menopausal status, histolog-
ical type, histological grade, depth of myometrial invasion, surgical
stage according to the International Federation of Gynaecology and
Obstetrics (FIGO) classification, vascular invasion, and presence of
metastatic disease. Information on peritoneal affection was available
in 126 patients, but that on lymph node involvement was very limited
because lymphadenectomy was performed in only 16 cases.
Tissue fractionation
Tumour specimens were promptly frozen in liquid nitrogen after
surgery and then kept at —70°C until assay. The percentage of
tumoral tissue (cancer cell plus stroma) present in each specimen
was almost 100% in most cases (selected under macroscopic inspec-
tion by the pathologist). Samples (100—200 mg) were homogenized
in ten volumes of buffer containing 10 mM tris-HCl, pH 7.4, 1.5 mM
disodium EDTA, 10 mM sodium molybdate, 0.1% monothio-
glycerol, 1 mM phenylmethylsulphonyl fluoride, 1 mg ml—1 apro-
tinin, 1 mM sodium orthovanadate and 10% glycerol. Aliquots of
homogenates were used to measure the total cellular p185HER-2/neu
(p185) content. The rest of the homogenates were centrifuged at
1000 g for 15 min at 4°C, and the supernatants were centrifuged
again at 105 000 g for 1 h at 4°C to obtain the cytosols.
Table 1 Distribution of cathepsin D levels according to clinicopathological parameters
Median Range Number of cases (%)
Parameter n (pmol mg–1 protein) P-value <40 pmol mg–1 protein P-value
Age at diagnosis (years)
<65 75 44 4–176 27 (36.0)
³65 81 44 0–243 ns 33 (40.7) ns
Menopausal status
Pre/peri 10 53 14–176 4 (40.0)
Post 146 44 0–243 ns 56 (38.4) ns
Histological type
Endometrioid 139 44 4–243 52 (37.4)
Other 17 42 0–114 ns 8 (47.1) ns
Histological grade
1 80 53 4–185 25 (33.3)
2 42 43 20–243 18 (42.9)
3 34 47 0–173 ns 17 (44.7) ns
Myometrial invasion
None–<50% 117 49 4–185 42 (36.5)
>50% 39 42 0–243 ns 18 (43.9) ns
Stage
I 114 47 4–185 41 (35.7)
II 23 45 14–243 10 (41.7)
III 19 44 0–173 ns 9 (52.9) ns
Vascular invasion
No 121 44 4–243 44 (36.4)
Yes 35 55 0–142 ns 16 (45.7) ns
Peritoneal cytology
Negative 115 44 8–243 42 (36.5)
Positive 11 35 0–142 ns 6 (54.5) ns
ns, non-significant.572 O Falcón et al
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Assays
Cat D was measured in the cytosol using a solid phase two-site
radiometric immunoassay (Elsa-Cath-D; Cis biointernational, Gif-
sur-Yvette, France). Briefly, cytosols were diluted to a protein
concentration of 1 mg ml—1 and the assay was performed in dupli-
cate after a further 81-fold dilution. The best cut-off level to
consider that a given specimen contained a high content of Cat D
was 40 pmol mg—1 protein (see below).
For the measurement of ER and PR, cytosols were diluted to
1 mg protein ml—1 with 0.1% bovine serum albumin (BSA) and
were incubated overnight in duplicate at 0—4°C with either 5 nM of
[3H]-oestradiol or 10 nM of [3H]R5020 (NEN, Boston, MA, USA),
in the presence or absence of a 200-fold excess of unlabelled
diethylstilboestrol or R5020, respectively, to correct for non-
specific binding. At the end of the incubation period, the unbound
steroid was removed by dextran-coated charcoal treatment (0.05%
dextran T-70, 0.5% activated charcoal). Tumours were classified
as ER or PR positive if the content of ER and PR was equal to or
greater than 10 and 30 fmol mg—1 protein respectively.
The total cellular p185 content was measured in the
homogenates from tumour samples by a commercial enzyme-
linked immunosorbent assay (ELISA) (human neu-oncoprotein
ELISA; Oncogene Science, Uniondale, NY, USA). Aliquots of
50 ml of the tissue homogenates were incubated for 5 min at room
temperature with 10 ml of antigen-extraction agent and centrifuged
at 14 000 g for 10 min at 4°C. The protein concentration of super-
natant was diluted to 10 mg ml—1, or further if necessary, and the
assay was performed in duplicate according to the instructions
given by the manufacturer. A level of p185 equal to or higher than
260 fmol mg—1 protein, previously validated by us in breast cancer
(Valer￿n et al, 1996), was used to consider that a given tumour
overexpressed the oncoprotein.
The protein concentration was estimated by the Bradford
method (Bio-Rad, Richmond, CA, USA) using BSA as a standard.
For flow cytometry analysis, fine-needle aspiration of tissue
samples was used for initial mechanical disaggregation. The aspirates
were flushed with buffer containing 3.4 mMtrisodium citrate, pH 7.6,
0.1% Nonidet P-40, 1.5 mM spermine tetrahydrochloride and 0.5 mM
Tris. The suspensions were then clarified by filtering through a 50-
mm nylon mesh and centrifuged at 200 g for 5 min. Pellets were
resuspended in 100 ml of buffer and treated according to the method
of Vindelov and Christensen (1990). Stained nuclei were analysed on
an EPICS XL-MCL cytometer (Coulter Corporation, Hialeah, FL,
USA). Quality control of the flow cytometer was carried out using
DNA-Check Epics Alignment Fluorospheres (Coulter). Peak inte-
grated red fluorescence, gated along the diagonal, was used to
analyse 20 000 nuclei, and data were stored in list mode. Half-peak
coefficients of variation were always lower than 5%. Generated
histograms were analysed for cell cycle compartments and back-
ground debris subtraction using the Multicycle software for cell cycle
analysis (Phoenix Flow Systems, San Diego, CA, USA). In accor-
dance with previous studies (Lukes et al, 1994), tumours with a DNA
index equal to or greater than 1.25 were considered aneuploid. The
best cut-off point to discriminate between high and low S-phase was
11% (see below).
Follow-up
All patients were routinely examined every 3 months for the first 2
years and then every 6 months. A subset of 97 patients, who were
followed for at least 2 years or until death, was selected to study
the prognostic value of the variables analysed. Time to event was
defined as the period of time from diagnosis to either the date of
recurrence for patients with a disease-free interval after surgery or
the date of surgery for patients who never became free of disease.
For the whole subset, the median follow-up time was 42 months
(range 0.2—91 months). There were 22 patients with either recur-
rent (n = 17) or persistent (n = 5) disease. Their median follow-up
time was 14 months (range 0.2—83 months). Among these patients,
15 (68.2%) died of endometrial cancer, including five out of five
(100%) patients with persistent disease and 10 out of 17 (58.8%)
patients with recurrent disease. The remaining 75 patients without
recurrent or persistent disease were alive at the last follow-up. The
median follow-up time of these patients was 49 months (range
24—91 months).
Statistical analysis
Correlations between Cat D and steroid receptors, p185 and S-
phase were performed by Spearman￿s rank correlation coefficient.
The non-parametric Mann—Whitney or Kruskal—Wallis tests were
used for comparison between the medians of two or more groups
respectively. The relationship between Cat D status and that of
other prognostic variables was examined in contingency tables
using the chi-squared or Fisher￿s exact tests. Cat D and S-phase
were dichotomized using the minimum P-value method by
selecting the best cut-off value that allowed the maximal separa-
tion between groups at low and high risk for persistence or relapse.
To confirm the statistical significance of the selected value, the
levels of the studied variables were logarithmically transformed
Table 2 Levels of continuous biological prognostic indicators in 156
endometrial tumours
Prognostic
variable Mean s.d. Median Minimum Maximum
Cat D 53 36 44 0 243
ER 106 113 72 0 737
PR 442 472 281 0 2069
p185 219 376 159 12 4030
S-phase 6.8 5.2 5.1 0.7 24.7
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Figure 1 Frequency distribution of cathepsin D values, logarithmically
transformed, in 156 endometrial tumour cytosols, divided at the selected cut-
off point of 40 pmol mg–1 protein. Numbers in parentheses indicate the
number of tumoursCathepsin D in endometrial cancer 573
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and the variable treated as a continuous covariate in a Cox model,
as proposed by Altman et al (1994). P-values for Cat D and S-
phase in the Cox analysis were 0.0062 and 0.0015 respectively.
Univariate survival analysis was performed using the log-rank test
in association with Kaplan—Meier analysis. The Cox proportional
hazards model, with forward step-wise selection of variables, was
applied for multivariable analysis. The likelihood ratio test was
used to test for variable selection. In these studies, all variables
were considered as binary, including age at diagnosis (‡ 65 years
vs <65 years), grade (3 vs 1 or 2), stage (II or III vs I), and treat-
ment (surgery plus radiotherapy vs surgery alone). The two-sided
test of significance with an alpha of 0.05 was used in all analyses.
Statistical analyses were performed using the SPSS for Windows
(version 6.1.3) statistical software (SPSS, Chicago, IL, USA).
RESULTS
Characteristics of the tumours
The characteristics of our tumour series are listed in Table 1. The
mean and median age of the patients was 65 years (range 29—93
years). Most of the patients were post-menopausal (93.6%), and the
predominant histological type was endometrioid (89.1%). Among
the 17 tumours of non-endometrioid histological type, five were
serous and 12 clear cell. Half of the tumours were well differentiated
(51.3%) and two-thirds were confined to the endometrium or
invaded less than half of the myometrium. Surgical stage I was
predominant (73.1%), vascular space involvement existed in 22.4%
of the patients, and 8.7% of cases had a positive peritoneal cytology.
The Cat D content of the tumours followed a gaussian distribu-
tion when the values were logarithmically transformed (Figure 1).
According to the selected cut-off point, 38.5% of tumours had a
low Cat D level, whereas 61.5% had a high content. The descrip-
tive statistic of all quantitatively analysed variables is shown in
Table 2. The number of positive specimens for ER and PR was
82.1% and 84% respectively. The p185 content was elevated in
17.9% of cases, and 17.9% of tumours had a high S-phase.
Furthermore, 16% of tumours were aneuploid, considering a DNA
index of 1.25 as the cut-off point.
Relationship between Cat D content and
clinicopathological or biological parameters
Table 1 also shows the relationship between Cat D levels and the
clinicopathological characteristics of patients. There was no asso-
ciation between the tumoral Cat D content, considered either as
continuous or categorical variable, and any of the established
prognostic parameters.
Spearman correlation analyses between Cat D and steroid
receptors, p185 and S-phase showed that Cat D did not correlate to
any of the quantitatively analysed variables, with the exception of
a weak positive correlation with p185 (r = 0.2;  P = 0.01).
Similarly, there was no association between Cat D content, consid-
ered either as a continuous or categorical variable, and the rest of
the biological variables analysed (Table 3).
Survival analysis
Results of the univariable survival analysis are shown in Table 4.
Age at diagnosis, high histological grade, advanced surgical stage,
Table 3 Distribution of cathepsin D levels according to biological parameters
Median Range Number of cases (%)
Parameter n (pmol mg–1 protein) P-value <40 pmol mg–1 protein P-value
ER
Negative 28 52 0–176 12 (42.9)
Positive 128 44 4–243 ns 48 (37.5) ns
PR
Negative 25 38 0–97 14 (56.0)
Positive 131 45 4–243 ns 46 (35.1) ns
p185
Low 128 44 0–243 53 (41.4)
High 28 53 20–157 ns 7 (25.0) ns
Ploidy
Diploid 131 44 4–243 51 (38.9)
Aneuploid 25 47 0–142 ns 9 (36.0) ns
S-phase
Low 128 44 0–243 58 (47.6)
High 28 48 14–176 ns 19 (55.9) ns
ns, non-significant. Cut-off levels of variables were as follows: ER, 10 fmol mg–1 protein; PR, 30 fmol mg–1 protein; p185, 260 fmol mg–1 protein; S-phase, 11%.
Table 4 Univariate survival analysis of risk factors for persistent or recurrent
endometrial cancer
Variable P-value
Age at diagnosis 0.045
Histological type 0.24
Histological grade 0.0000
Myometrial invasion 0.38
Stage 0.0000
Vascular invasion 0.0028
Peritoneal cytology 0.0000
Cathepsin D 0.0015
Oestrogen receptor 0.027
Progesterone receptor 0.0000
p185 0.56
Ploidy 0.0012
S-phase 0.0000
Treatment 0.47
Cut-off levels for biological variables as in Table 3.574 O Falcón et al
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low levels of Cat D, negative ER and PR status, aneuploidy, high
S-phase, vascular invasion and positive peritoneal cytology were
positively associated with persistent or recurrent disease. The multi-
variate survival analysis (Table 5), performed without considering
peritoneal cytology because of the small number of patients in
which it was estimated (n = 73), showed that histological grade,
surgical stage, Cat D and PR were significantly associated with
disease-free survival. Among them, Cat D had one of the higher risk
ratios; thus, in a given patient with a low Cat D content, the hazard
risk of persistent or recurrent disease was 2.19-fold higher than in
those patients with a Cat D level above the cut-off point. The Kaplan
and Meier curve for Cat D is depicted in Figure 2. Although 39% of
patients with low Cat D levels had persistent or recurrent disease at
the last follow-up, this circumstance existed in only 10.7% of those
patients with a Cat D content above the cut-off point (P = 0.0015).
To discard the possibility that the treatment modality biased these
results, a separate analysis was performed for patients treated with
surgery alone, or with surgery and radiotherapy. In each subgroup,
patients with a low Cat D content had a significantly worse outcome
than patients with high Cat D (Table 6).
DISCUSSION
The literature contains very little information about the role of Cat
D in endometrial cancer. To date, only six articles deal with Cat D
expression in this tumour type, and its prognostic significance has
only been studied in one of them. These studies were performed on
relatively small series, because only one group included more than
100 cases (L￿sch et al, 1996). In one study, Cat D levels were
quantified by ELISA (Maudelonde et al, 1990), and in three
(Nazeer et al, 1992; Scambia et al, 1995; Sanfilippo et al, 1996) by
an immunoradiometric (IRMA) procedure similar to that used by
us. In another article, Cat D was detected by immunohistochem-
istry (IHC) (L￿sch et al, 1996). The two procedures (IRMA and
IHC) were compared in one article (Nazeer et al, 1994) using a
patient series very similar to one in which Cat D concentration was
determined by IRMA by the same group (Nazeer et al, 1992).
It has been suggested that the tumoral cytosolic Cat D values
obtained by the immunoradiometric assay used in this work may
be impaired by the relative contribution of non-tumoral cells (Isola
et al, 1993), which makes the IHC method more specific.
However, some authors have reported that total cytosolic Cat D
correlates well with Cat D content in cancer cells (Roger et al,
1994), and that Cat D levels in cancer and stromal cells are directly
correlated (Ravdin et al, 1994). In addition, the assessment of Cat
D content by the immunoradiometric assay seems likely to give
reliable and comparable interstudy results as assessed by the
EORTC Receptor Study Group (Benraad et al, 1992).
Our results showed that Cat D is expressed in variable amounts
in endometrial cancer, its levels being slightly lower than or
similar to those reported by some authors in breast cancer
(Foekens et al, 1993; Marsigliante et al, 1994; Gion et al, 1995;
Valer￿n et al, 1997). Our data in endometrial cancer are similar to
those published by Sanfilippo et al (1996) and higher than those
reported by three other groups (Maudelonde et al, 1990; Nazeer et
al, 1992; Scambia et al, 1995). The reasons underlying these diver-
gent results are not clear because most of these authors used essen-
tially the same methodology as that used by us.
We did not find an association between Cat D levels and those
of the established clinicopathological prognostic factors, which
Table 5 Multivariate survival analysis of risk factors for persistent or recurrent endometrial cancer
Variable Wald chi-squared RR (95% Cl)a P-value
Histological grade
3 vs 1 or 2 3.73 1.6 (0.99–2.58) 0.054
Stage
II or III vs I 10.71 2.25 (1.38–3.66) 0.0011
Cathepsin D
Low vs High 9.18 2.19 (1.32–3.65) 0.0024
Progesterone receptor
Negative vs positive 5.58 1.9 (1.12–3.23) 0.018
aRR (95% CI), estimated risk ratio (95% confidence interval). For selected cut-off points of biological variables see Table 3.
Table 6 Survival rates by type of treatment and cathepsin D status
Treatment n Cat D (%) P-value
Low High
Surgery 54 35.7 89.9 <0.05
Surgery plus 43 48.8 87 <0.05
radiotherapy
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Figure 2 Kaplan and Meier survival curve of patients stratified according to
cathepsin D status defined by the cut-off value of 40 pmol mg–1 protein (- - -)
Cat D high; (— —) Cat D low. Numbers in parentheses indicates the number of
failures/total number of patients in each group. The difference was significant
using the log-rank test. P = 0.0015Cathepsin D in endometrial cancer 575
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agrees with data reported by L￿sch et al (1996), and contrasts with
other reports in which Cat D content was positively associated
with histological type (Nazeer et al, 1992), myometrial invasion
(Maudelonde et al, 1990; Nazeer et al, 1992), and grade of differ-
entiation (Nazeer et al, 1992). Conversely, Scambia et al (1995)
reported an inverse association between Cat D and myometrial
invasion and stage. One possible explanation for these discrepan-
cies could rely on the relatively small series which most of the
cited studies used.
There is evidence that Cat D gene expression is increased by
progesterone, but not by oestrogen, both in rat uterus (Elangovan
et al, 1980) and in normal human endometrium (Maudelonde et al,
1990). We did not find any correlation or association between Cat
D and steroid hormone receptors, either in the whole tumour series
or in the subgroup of PR-positive tumours (data not shown). These
results are in accordance with two previous reports (Maudelonde
et al, 1990; Nazeer et al, 1992) and disagree with another in which
a positive association between Cat D and ER/PR status was found
(Scambia et al, 1995). Our data suggest that in endometrial cancer
the hormone dependence of Cat D expression is lost or, alterna-
tively, the role that growth factors play in its regulation are more
important than that exerted by sex hormones.
There are no data in the literature regarding the relationship
between Cat D and p185, ploidy and S-phase in endometrial
cancer. We could not find any correlation or association between
Cat D and ploidy and S-phase. Regarding p185, we observed a
weak, although significant, positive correlation between these two
variables, a finding that has also been described in breast cancer
(Seshadri et al, 1994; Valer￿n et al, 1997).
To establish the prognostic value of a set of variables, a large
series of patients followed for a long time is desirable. Our series
did not completely fulfil these criteria, and for this reason we
selected a subset of patients followed for at least 2 years or until
death. Because the follow-up period was relatively short (median
46 months), we used survival analysis for persistent or recurrent
disease, a clinical condition which is difficult to cure, instead of
overall survival, which would require a more prolonged follow-up.
As expected, univariate survival analysis confirmed the prog-
nostic value of known clinicopathological prognostic factors,
including age at diagnosis, histological type, histological grade,
surgical stage, vascular invasion and peritoneal cytology, which is
in accordance with previous reports (Christopherson et al, 1983;
Creasman et al, 1987; Morrow et al, 1991; Barakat et al, 1997).
However, histological type and depth of myometrial invasion
lacked significance. This analysis also showed the prognostic
significance of Cat D, ER, PR, ploidy and S-phase, but not that of
p185. Multivariate analysis led us to determine the significance of
biological factors in relation to conventional clinicopathological
prognostic parameters. Our results showed that a high grade of
differentiation, advanced surgical stage, low levels of cathepsin D
and PR negativity are predictive of poor outcome. Therefore, and
contrary to what might be expected, Cat D seems to be a
favourable prognostic factor in endometrial cancer. This finding
contrasts with that reported by L￿sch et al (1996) using immuno-
histochemistry to detect the protease. However, Scambia et al
(1995) reported that high Cat D levels might be a good prognostic
factor in endometrial cancer, although they could not obtain reli-
able survival analysis. As far as we know, this is the first time in
which such an association has been described in endometrial
cancer, although before us Henry et al (1990) found similar results
in breast cancer. One could argue that high Cat D content reflects
the functional integrity of the steroid hormone receptor pathway
(Henry et al, 1990), and that high levels of Cat D, as well as PR-
positivity, are predictive of good prognosis. However, in our study,
we did not find any relationship between Cat D and these recep-
tors. It may also be possible that the acidic conditions needed for
the Cat D to be active (Morisset et al, 1986) do not arise in
endometrial cancer, but this does not explain the favourable inci-
dence on prognosis of low Cat D levels. The question, then, is
open to future research.
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